Brokers

Brokers Issue Forecasts for Hookipa Pharma Inc’s Q2 2022 Earnings (NASDAQ:HOOK)


Hookipa Pharma Inc (NASDAQ:HOOKGet Rating) – Investment analysts at SVB Leerink lifted their Q2 2022 earnings per share estimates for Hookipa Pharma in a research note issued on Monday, May 16th. SVB Leerink analyst A. Berens now expects that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.70). SVB Leerink has a “Outperform” rating and a $4.00 price objective on the stock. SVB Leerink also issued estimates for Hookipa Pharma’s Q3 2022 earnings at ($0.39) EPS, Q4 2022 earnings at ($0.34) EPS, FY2022 earnings at ($1.47) EPS, FY2023 earnings at ($1.13) EPS, FY2024 earnings at ($1.11) EPS, FY2025 earnings at ($1.01) EPS and FY2026 earnings at ($0.66) EPS.

Hookipa Pharma (NASDAQ:HOOKGet Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.28). Hookipa Pharma had a negative net margin of 523.54% and a negative return on equity of 70.82%. During the same period in the prior year, the firm earned ($0.53) EPS.

Other research analysts have also recently issued research reports about the stock. Truist Financial cut their target price on shares of Hookipa Pharma from $23.00 to $16.00 in a research note on Wednesday, February 16th. Zacks Investment Research downgraded Hookipa Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, February 10th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Hookipa Pharma in a report on Friday, March 25th. Finally, Royal Bank of Canada lowered their target price on Hookipa Pharma from $11.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, March 25th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $7.93.

Shares of HOOK stock opened at $1.54 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.69 and a quick ratio of 3.69. Hookipa Pharma has a 12-month low of $1.25 and a 12-month high of $19.49. The firm has a 50-day moving average price of $1.68 and a 200 day moving average price of $2.27.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOOK. Parametric Portfolio Associates LLC bought a new stake in shares of Hookipa Pharma during the fourth quarter worth $44,000. Banque Cantonale Vaudoise acquired a new stake in Hookipa Pharma in the first quarter worth about $46,000. LPL Financial LLC bought a new stake in Hookipa Pharma during the 3rd quarter worth about $62,000. HighVista Strategies LLC acquired a new position in Hookipa Pharma during the 3rd quarter valued at about $71,000. Finally, Barclays PLC boosted its stake in shares of Hookipa Pharma by 94.4% in the 4th quarter. Barclays PLC now owns 31,822 shares of the company’s stock valued at $74,000 after purchasing an additional 15,454 shares during the last quarter. 57.65% of the stock is owned by institutional investors.

Hookipa Pharma Company Profile (Get Rating)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Further Reading

Earnings History and Estimates for Hookipa Pharma (NASDAQ:HOOK)



Receive News & Ratings for Hookipa Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hookipa Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.